Inogen (NASDAQ:INGN) EVP Sells $70,328.10 in Stock

Inogen, Inc (NASDAQ:INGN) EVP Boyer Jennifer Yi sold 10,770 shares of the company’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $6.53, for a total value of $70,328.10. Following the transaction, the executive vice president directly owned 15,977 shares in the company, valued at approximately $104,329.81. This trade represents a 40.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Inogen Trading Up 0.8%

INGN stock traded up $0.05 during trading on Tuesday, reaching $6.14. 609,667 shares of the stock were exchanged, compared to its average volume of 359,619. The firm’s 50 day moving average is $6.60 and its 200 day moving average is $6.49. Inogen, Inc has a twelve month low of $5.34 and a twelve month high of $9.13. The firm has a market cap of $166.22 million, a P/E ratio of -6.67 and a beta of 1.60.

Inogen (NASDAQ:INGN) last posted its quarterly earnings results on Thursday, May 7th. The medical technology company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.06). Inogen had a negative return on equity of 12.90% and a negative net margin of 7.08%.The firm had revenue of $85.11 million for the quarter, compared to analyst estimates of $82.35 million. As a group, analysts predict that Inogen, Inc will post -0.77 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on INGN. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inogen in a research note on Friday, May 8th. Freedom Capital raised Inogen to a “strong-buy” rating in a research note on Tuesday, April 7th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Inogen has an average rating of “Moderate Buy” and an average target price of $14.00.

Institutional Trading of Inogen

Several institutional investors and hedge funds have recently modified their holdings of the stock. Armistice Capital LLC raised its stake in shares of Inogen by 46.3% in the fourth quarter. Armistice Capital LLC now owns 1,264,000 shares of the medical technology company’s stock worth $8,494,000 after purchasing an additional 400,000 shares during the last quarter. Kent Lake PR LLC raised its stake in shares of Inogen by 5.7% in the second quarter. Kent Lake PR LLC now owns 1,061,294 shares of the medical technology company’s stock worth $7,461,000 after purchasing an additional 57,700 shares during the last quarter. Ameriprise Financial Inc. grew its holdings in shares of Inogen by 0.8% in the second quarter. Ameriprise Financial Inc. now owns 881,100 shares of the medical technology company’s stock valued at $6,194,000 after acquiring an additional 6,573 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Inogen by 7.9% in the second quarter. Geode Capital Management LLC now owns 615,279 shares of the medical technology company’s stock valued at $4,326,000 after acquiring an additional 44,860 shares in the last quarter. Finally, Royce & Associates LP grew its holdings in shares of Inogen by 15.2% in the third quarter. Royce & Associates LP now owns 600,968 shares of the medical technology company’s stock valued at $4,910,000 after acquiring an additional 79,238 shares in the last quarter. 89.94% of the stock is owned by hedge funds and other institutional investors.

Inogen Company Profile

Inogen, Inc (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.